+

WO1989006974A3 - Epitopes de cellules t a titre de molecules porteuses pour vaccins conjugues - Google Patents

Epitopes de cellules t a titre de molecules porteuses pour vaccins conjugues Download PDF

Info

Publication number
WO1989006974A3
WO1989006974A3 PCT/US1989/000388 US8900388W WO8906974A3 WO 1989006974 A3 WO1989006974 A3 WO 1989006974A3 US 8900388 W US8900388 W US 8900388W WO 8906974 A3 WO8906974 A3 WO 8906974A3
Authority
WO
WIPO (PCT)
Prior art keywords
conjugate vaccines
conjugates
cell epitope
epitopes
carriers molecule
Prior art date
Application number
PCT/US1989/000388
Other languages
English (en)
Other versions
WO1989006974A2 (fr
Inventor
Garvin Bixler
Subramonia Pillai
Richard Insel
Original Assignee
Praxis Biolog Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Biolog Inc filed Critical Praxis Biolog Inc
Priority to DE68917126T priority Critical patent/DE68917126T2/de
Priority to EP89908669A priority patent/EP0399001B1/fr
Publication of WO1989006974A2 publication Critical patent/WO1989006974A2/fr
Publication of WO1989006974A3 publication Critical patent/WO1989006974A3/fr
Priority to FI903292A priority patent/FI104374B/fi
Priority to NO902909A priority patent/NO179164C/no
Priority to DK199001829A priority patent/DK174416B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Optical Couplings Of Light Guides (AREA)

Abstract

La présente invention concerne de nouveaux épitopes de cellules T de produits bactériens. On peut utiliser les épitopes de l'invention dans la préparation de conjugués entre les épitopes et des antigènes, des haptènes, ou des déterminants antigéniques médicalement utiles. Ces conjugués peuvent provoquer des réactions d'anticorps similaires à des conjugués d'antigènes couplés de manière covalente à des protéines porteuses, et dans une composition de vaccins, fournir des vaccins conjugués sûrs et plus économiques.
PCT/US1989/000388 1988-02-01 1989-01-31 Epitopes de cellules t a titre de molecules porteuses pour vaccins conjugues WO1989006974A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DE68917126T DE68917126T2 (de) 1988-02-01 1989-01-31 T-zellen-epitope als träger für einen konjugierten impfstoff.
EP89908669A EP0399001B1 (fr) 1988-02-01 1989-01-31 Epitopes de cellules t a titre de molecules porteuses pour vaccins conjugues
FI903292A FI104374B (fi) 1988-02-01 1990-06-29 T-solu-epitooppi-oligopeptidejä ja niitä sisältävien konjugaattien valmistus
NO902909A NO179164C (no) 1988-02-01 1990-06-29 Fremgangsmåte for fremstilling av et immunogenkonjugat
DK199001829A DK174416B1 (da) 1988-02-01 1990-07-31 Oligopeptider, immunogene konjugater heraf med et antigen samt vacciner indeholdende disse konjugater

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15068888A 1988-02-01 1988-02-01
US150,688 1988-02-01

Publications (2)

Publication Number Publication Date
WO1989006974A2 WO1989006974A2 (fr) 1989-08-10
WO1989006974A3 true WO1989006974A3 (fr) 1989-08-24

Family

ID=22535596

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1989/000388 WO1989006974A2 (fr) 1988-02-01 1989-01-31 Epitopes de cellules t a titre de molecules porteuses pour vaccins conjugues

Country Status (10)

Country Link
EP (1) EP0399001B1 (fr)
JP (1) JP2921574B2 (fr)
AT (1) ATE109008T1 (fr)
AU (1) AU634153B2 (fr)
CA (2) CA1340956C (fr)
DE (1) DE68917126T2 (fr)
DK (1) DK174416B1 (fr)
FI (1) FI104374B (fr)
NO (1) NO179164C (fr)
WO (1) WO1989006974A2 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2071478A1 (fr) * 1989-10-27 1991-04-28 Jeffery A. Bluestone Methodes et compositions favorisant l'immunopotentialisation
GB8924438D0 (en) * 1989-10-31 1989-12-20 Hoffmann La Roche Vaccine composition
WO1992005192A1 (fr) * 1990-09-18 1992-04-02 Biotech Australia Pty. Limited Epitopes des lymphocytes t
WO1993011157A1 (fr) * 1991-11-27 1993-06-10 The Council Of The Queensland Institute Of Medical Research VACCIN ET PEPTIDES CONTRE LA MALARIA COMPRENANT UN EPITOPE DE CELLULE T HUMAINE DE PROTEINE CIRCUMSPOROZOITE DE $i(P.VIVAX)
IL105503A (en) * 1992-04-28 1999-05-09 Astra Ab Carbon peptide couplets capable of eliciting an immune response of T cells
WO1994002508A2 (fr) * 1992-07-22 1994-02-03 Proteus Molecular Design Limited Antigenes polypeptidiques de mycobacterium bovis
DE69322645T2 (de) * 1992-07-31 1999-05-20 Medeva Holdings B.V., Amsterdam Expression rekombinanter fusionsproteine in attenuierten bakterien
WO1994005311A1 (fr) 1992-08-27 1994-03-17 Deakin Research Limited Analogues peptidiques de synthese a modifications retro, inverse ou retro-inverse
DK140992D0 (da) * 1992-11-24 1992-11-24 Ole Buchardt Fremgangsmaade til frembringelse af antistoffer mod haptener og andre b-celle-antigener, antistoffer opnaaet ved fremgangsmaaden og anvendelse af disse antistoffer til fremstilling af vacciner, isaer til veterinaermedicinsk brug
US5759551A (en) * 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
ATE215124T1 (de) * 1993-07-30 2002-04-15 Medeva Holdings Bv Rekombinante tetc-fusionsprotein enthaltene impfstoffzusammensetzungen
GB9401787D0 (en) 1994-01-31 1994-03-23 Medeva Holdings Bv Vaccine compositions
GB9401795D0 (en) * 1994-01-31 1994-03-23 Medeva Holdings Bv Vaccines
GB2295394B (en) * 1994-01-31 1997-09-24 Medeva Holdings Bv DNA encoding a fusion protein comprising the C fragment of tetanus toxin
WO1995024216A1 (fr) * 1994-03-07 1995-09-14 Auckland Uniservices Limited Prevention du diabete
ATE254930T1 (de) * 1995-03-31 2003-12-15 Xenova Res Ltd Hapten-träger-konjugate zur anwendung in der drogen-missbrauchs-therapie
US5840307A (en) * 1995-03-31 1998-11-24 Immulogic Pharmacuetical Corp. Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation
US5843462A (en) * 1995-11-30 1998-12-01 Regents Of The University Of Minnesota Diphtheria toxin epitopes
US7709002B1 (en) 1996-04-19 2010-05-04 The United States Of America As Represented By The Department Of Health And Human Services Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes
AU2734397A (en) 1996-04-19 1997-11-12 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Mutated ras peptides for generation of cd8+ cytotoxic t lymphocytes
GB9713156D0 (en) * 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
US6025468A (en) 1998-06-20 2000-02-15 United Biomedical, Inc. Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
TWI229679B (en) 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
DE19856052A1 (de) * 1998-12-04 2000-06-08 Deutsches Krebsforsch Konjugat zur Anreicherung in neuronalen Zellen
EP1343821A2 (fr) 2000-11-09 2003-09-17 Immunolex Laboratories Procede de production d'anticorps par immunisation avec des conjugues de molecules couplees a des proteines a charge modifiee
WO2010040847A2 (fr) 2008-10-10 2010-04-15 Era Biotech, S.A. Corps de protéines recombinantes en tant qu'adjuvants spécifiques d'immunogènes
US9358302B2 (en) * 2009-03-23 2016-06-07 The Brigham And Women's Hospital, Inc. Glycoconjugate vaccines
EP2418284A1 (fr) 2010-08-13 2012-02-15 ERA Biotech, S.A. Séquences de polypeptides induisant le corps protéiques
EP2870974A1 (fr) * 2013-11-08 2015-05-13 Novartis AG Vaccins conjugués de salmonelle
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
AU2017388891C1 (en) 2016-12-30 2025-04-17 Vaxcyte, Inc. Polypeptide-antigen conjugates with non-natural amino acids
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
BR112020026899A2 (pt) 2018-07-04 2021-03-30 Vaxcyte, Inc. Melhorias em conjugados imunogênicos
WO2020010016A1 (fr) 2018-07-04 2020-01-09 Sutrovax, Inc. Conjugués immunogènes auto-adjuvés
WO2020010000A1 (fr) 2018-07-04 2020-01-09 Sutrovax, Inc. Procédés améliorés pour la préparation de conjugués immunogènes

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0172107A1 (fr) * 1984-08-10 1986-02-19 Praxis Biologics, Inc. Conjugués immunogènes d'unité secondaire d'entérotoxine LT-B d'E. coli et polymères capsulaires
EP0186576A2 (fr) * 1984-12-20 1986-07-02 Merck & Co. Inc. Polysaccharides bactériens neutres modifiés de manière covalente, conjugés stables covalents entre ces polysaccharides et des protéines immunogéniques et méthodes de préparation de ces polysaccharides et conjugués
EP0245045B1 (fr) * 1986-05-05 1993-11-03 Praxis Biologics, Inc. Conjugués immunogènes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0172107A1 (fr) * 1984-08-10 1986-02-19 Praxis Biologics, Inc. Conjugués immunogènes d'unité secondaire d'entérotoxine LT-B d'E. coli et polymères capsulaires
EP0186576A2 (fr) * 1984-12-20 1986-07-02 Merck & Co. Inc. Polysaccharides bactériens neutres modifiés de manière covalente, conjugés stables covalents entre ces polysaccharides et des protéines immunogéniques et méthodes de préparation de ces polysaccharides et conjugués
EP0245045B1 (fr) * 1986-05-05 1993-11-03 Praxis Biologics, Inc. Conjugués immunogènes

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Infection and Immunity, vol. 55, no. 11, November 1987, American Society for Microbiology (US), L.D. Lise et al.: "Enhanced epitopic response to a synthetic human malarial peptide by preimmunization with tetanus toxoid carrier", pages 2658-2661 *
Infection and Immunity, vol. 55, no. 6, June 1987, American Society for Micro-biology (US), M.E. Jolivet et al.: "Induction of biologically active antibodies by a polyvalent synthetic vaccine constructed without carrier", pages 1498-1502 *
Nature, vol. 300, 12 November 1987, M.J. Francis et al.: "Non-responsiveness to a foot and mouth disease virus peptide overcome by addition of foreign helper T-cell determinants ", pages 168-170 *
Nucleic Acids Research, vol. 14, no. 19, 19 November 1986, IRL Press Ltd (Oxford, GB), N.F. Fairweather et al.: "The complete nucleotide sequence of tetanus toxin", pages 7809-7812 *
Proceedings of the National Academy of Sciences of the USA, vol. 80, no. 22, November 1983, L. Greenfield et al.: "Nucleotide sequence of the structural gene for diptheria toxin carried by coryne-bacteriophage beta", pages 6853-6857 *
Science, vol. 235, 27 February 1987, M.F. Good et al.: "Construction of synthetic immunogen: use of new T-helper epitome on malaria circum-sporoziteprotein", pages 1059-1062 *
The European Journal of Immunology, vol. 16, 1986,, VCH Verlagsgesellschaft mbh, (Weinheim, DE), F. Triebel et al.: "Immune response to diptheria toxin and to different CNBr fragments: evidence for different B and T cell reactivities", pages47-53 *
The Journal of Immunology, vol. 138, no. 12, 15 June 1987, The American Association of Immunologists (US), D.R. Milich et al.: "A single 10-residue pre-S(1) peptide can prime T cell help for antibody production to multiple epitopes within the pre-S(1), pre-S(2), and S regions of HBsAg", pages 4457 -4465 *
The Journal of Immunology, vol. 142, no. 2, 15 January 1989, The American Association of Immunologists (US), S. Demotz et al.: "Delineation of several DR-restricted tetanus toxin T cell epitopes", pages 394-402 *

Also Published As

Publication number Publication date
DK182990D0 (da) 1990-07-31
FI104374B (fi) 2000-01-14
NO902909D0 (no) 1990-06-29
JPH03502691A (ja) 1991-06-20
WO1989006974A2 (fr) 1989-08-10
JP2921574B2 (ja) 1999-07-19
FI903292A0 (fi) 1990-06-29
CA1340958C (fr) 2000-04-11
ATE109008T1 (de) 1994-08-15
EP0399001B1 (fr) 1994-07-27
NO179164C (no) 1996-08-21
AU3065489A (en) 1989-08-25
AU634153B2 (en) 1993-02-18
EP0399001A1 (fr) 1990-11-28
DK174416B1 (da) 2003-02-17
DK182990A (da) 1990-07-31
DE68917126D1 (de) 1994-09-01
DE68917126T2 (de) 1995-02-02
NO179164B (no) 1996-05-13
CA1340956C (fr) 2000-04-11
NO902909L (no) 1990-08-27

Similar Documents

Publication Publication Date Title
WO1989006974A3 (fr) Epitopes de cellules t a titre de molecules porteuses pour vaccins conjugues
RU95105991A (ru) Конъюгат, вакцина, способы усиления иммуногенности, способы иммунизации
CA2188284C (fr) Compositions de polysaccharides de streptocoques du groupe a ayant des proprietes immunogenes et procedes associes
IL104696A0 (en) Dual carrier immunogenic construct and a vaccine containing the same
HK1143950A1 (en) Artificial t helper cell epitopes as immune stimulators for synthetic peptide immunogens
WO1998058668A3 (fr) VACCIN CONTENANT UN ANTIGENE DE $i(BORDETELLA PERTUSSIS)
NO974727L (no) Immunogene og immunostimulatoriske oligosakkarid sammensetninger og fremgangsmåter for fremstilling derav
WO1999052548A3 (fr) Vaccins conjugues pour la prevention contre les caries dentaires
AU3313789A (en) Haemophilus influenza type B oxidized polysaccharide-outer membrane protein conjugate vaccine
US6165468A (en) Antigenic carbohydrate linked to an immunogenic carrier
RU93048161A (ru) Комбинированная педиатрическая вакцина с усиленной иммуногенностью каждого вакционного компонента
AU4803785A (en) Cross-reactive and protective epitopes of circumsporozoite proteins
IL107387A (en) Combination pediatric vaccine with enhanced immunogenicity of each vaccine component
AU7547987A (en) Method of preparation and use for feline leukemia virus antigens
CA2133108A1 (fr) Vaccin a base de toxoide contre pasteurella haemolytica type a-1
Michon et al. Combination conjugate vaccines against multiple serotypes of group B streptococci
WO1990015132A3 (fr) Gene endoflagellaire clone de treponema hyodysenteriae

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU DK FI JP NO

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE FR GB IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU DK FI JP NO

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 903292

Country of ref document: FI

WWE Wipo information: entry into national phase

Ref document number: 1989908669

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1989908669

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1989908669

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 903292

Country of ref document: FI

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载